Amyloid fibril detection probe

A curcumin derivative that binds to amyloid fibers and emits infrared light facilitates non-invasive detection and treatment by enabling infrared imaging and neutron beam therapy, addressing the limitations of current detection methods.

JP2024163697AActive Publication Date: 2024-11-22KINKI UNIVERSITY
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2023079529
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-12
Publication Date
2024-11-22
Estimated Expiration
2043-05-12

AI Technical Summary

Technical Problem

Current methods for detecting and observing amyloid fibrils in vivo are cumbersome, requiring large equipment like gamma ray imaging devices, and lack the capability for simultaneous treatment.

Method used

A novel curcumin derivative that selectively binds to amyloid fibers and emits light by infrared rays, allowing for non-invasive detection and potential treatment through neutron beam capture therapy.

Benefits of technology

Enables easy estimation of amyloid fiber distribution and amount using infrared imaging, high-resolution tomographic imaging with MRI, and targeted destruction of amyloid fibers through neutron beam therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163697000001_ABST
    Figure 2024163697000001_ABST
Patent Text Reader

Abstract

To provide an effective technique to enable amyloid fibrils formed within the body to be observed in vivo from outside the body.SOLUTION: The present invention provides an amyloid fibril detection probe that binds to amyloid β amyloid fibrils, containing a specific curcumin derivative, for example, a derivative represented by the following formula.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a probe compound for detecting and observing amyloid fibrils in the body from outside the body. [Background technology]

[0002] More than 30 types of diseases, including Alzheimer's disease and Parkinson's disease, have been reported to be caused by insoluble amyloid fibrils derived from various types of proteins. However, the detailed pathological mechanisms of these diseases remain unknown.

[0003] One of the treatment methods being considered is a method using antibodies. For example, aducanumab (BIIB037) is known as a human monoclonal antibody that selectively binds to the aggregated form of beta-amyloid (Aβ) peptide, and it has been reported that amyloid plaques (amyloid fibrils) can be reduced by specifying the administration method of such a monoclonal antibody (Patent Document 1).

[0004] Meanwhile, methods for detecting amyloid fibrils include the thioflavin fluorescence method, staining with Congo Red, staining with FSB, and ELISA using an antibody that recognizes amyloid fibrils (Patent Document 2).

[0005] As a method for detecting the deposition of amyloid fibrils in vivo, a method has been proposed in which a compound represented by formula (99) is radiolabeled at a carbon atom and detected by gamma ray imaging, magnetic resonance imaging, or magnetic resonance spectroscopy (Patent Document 3).

[0006] [ka]

[0007] [In the formula, R 1is hydrogen, -OH, -NO2, -CN, -COOR, -OCH2OR, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy or halo, where R 1 one or more of the atoms may be a radiolabeled atom; R is a C1-C6 alkyl, where one or more of the carbon atoms may be a radiolabeled atom; R 2 is hydrogen, non-radioactive halo or radioactive halo; R 3 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl; R 4 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, where R 2 is hydrogen or a non-radioactive halo, then the alkyl, alkenyl or alkynyl contains a radioactive carbon or is substituted with a radioactive halo; However, R 1 is hydrogen or -OH, and R 2 is hydrogen and R 4 but- 11 If CH3, R 3 is C2-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl; In addition, R 1 is hydrogen and R 2 is hydrogen and R 4 -CH2CH2CH2 18 When R is F, R3 is C2-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl; or a pharma- ceutically acceptable salt, hydrate, solvate, or prodrug thereof. [Prior art documents] [Patent documents]

[0008] [Patent Document 1] JP 2023-11002 A [Patent Document 2] JP 2020-188700 A [Patent Document 3] Special Publication No. 2006-522104 Summary of the Invention [Problem to be solved by the invention]

[0009] Observing amyloid fibers generated in the body in vivo is a necessary technique for treating diseases related to amyloid fibers. In this respect, the method of Patent Document 2 shows a certain degree of effectiveness. However, gamma ray imaging and the like require a huge device. Even if it is a simpler device, if there is one that can observe amyloid fibers in vivo, it is thought that it will contribute greatly to diagnosis. Furthermore, it can be said to be even more effective if it can play a part in treatment at the same time as observation. [Means for solving the problem]

[0010] The present invention has been conceived in view of the above problems, and provides a novel curcumin derivative, and a probe that selectively binds to amyloid fibers having the curcumin derivative and emits light when exposed to infrared light, thereby enabling the observation of amyloid fibers.

[0011] Specifically, the curcumin derivative according to the present invention is characterized by having a structure represented by formulas (2) to (8) and (10) to (14).

[0012] [ka]

[0013] [ka]

[0014] [ka]

[0015] [ka]

[0016] [ka]

[0017] [ka]

[0018] [ka]

[0019] [ka]

[0020] [ka]

[0021] [ka]

[0022] [ka]

[0023] [ka]

[0024] Furthermore, the amyloid fiber detection probe according to the present invention that binds to amyloid-β amyloid fibers contains at least one of the curcumin derivatives represented by formulas (4), (5), (6), (10), and (14).

[0025] Furthermore, the amyloid fibril detection probe according to the present invention that binds to α-synuclein amyloid fibrils contains at least one curcumin derivative represented by formula (3), formula (4), formula (7), or formula (8). Effect of the Invention

[0026] The amyloid fiber detection probe according to the present invention selectively binds to amyloid fibers and emits light by infrared rays, so that the light emission can be detected through the skin. Therefore, the distribution and amount of amyloid fibers can be easily estimated by using an infrared light emitting device and an infrared camera. In addition, it is possible that the amyloid fibers themselves can be destroyed by continuing to emit near-infrared light.

[0027] In addition, the amyloid fibril detection probe according to the present invention can be relatively easily incorporated into the structure. 13 Since it can contain C or F, it is possible to obtain high-resolution cross-sectional images of amyloid fibrils using a nuclear magnetic resonance (MRI) device.

[0028] Furthermore, since the amyloid fiber detection probe according to the present invention contains boron in its structure, it may be possible to perform neutron capture therapy on the bound amyloid fibers, thereby decomposing the amyloid fibers. [Brief description of the drawings]

[0029] [Figure 1] FIG. 1 shows a concept of biosynthesis of the curcumin analogues according to the present invention. [Diagram 2] FIG. 1 shows precursors in the biosynthesis of curcumin analogues. [Diagram 3] FIG. 2 shows the structure of a BF2-modified acurcumin analogue according to the present invention. [Figure 4] FIG. 2 shows the structure of a BF2-modified acurcumin analogue according to the present invention. [Diagram 5] FIG. 2 shows the structure of a BF2-modified acurcumin analogue according to the present invention. [Figure 6]FIG. 1 shows the fluorescence emission characteristics of an amyloid fibril detection probe. [Figure 7] FIG. 1 shows how amyloid β binds to amyloid fibrils. [Figure 8] This is an SDS-PAGE photograph showing the selection of BF2-modified acurcumin analogs that bind to amyloid β amyloid fibrils. [Figure 9] This is a Native-PAGE photograph showing the selection of BF2-modified acurcumin analogs that bind to synuclein amyloid fibrils. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] The amyloid fiber detection probe according to the present invention will be described below with reference to the drawings and examples. Note that the following description illustrates one embodiment of the present invention and one example, and the present invention is not limited to the following description. The following description can be modified within the scope of the present invention.

[0031] The amyloid fiber detection probe according to the present invention is a derivative obtained from curcumin and generally has a structure of formula (100).

[0032] [ka]

[0033] The coordination numbers indicate the numbers of the basic skeleton of curcumin. The functional groups bonded to the left and right benzene rings with the 1st position as the center are designated as Rp1 and Rp2. There are no particular limitations on each functional group, and the functional group Rp1 and the functional group Rp2 may each be multiple functional groups. In addition, the functional group Rp1 and the functional group Rp2 may be the same. Hereinafter, for the sake of explanation, the right side of the 1st position is called the right site, and the left side is called the left site.

[0034] The amyloid fiber detection probe according to the present invention, among those having this structure, has fluorescence emission in the infrared range and has binding ability to amyloid fibers. These amyloid fiber detection probes were produced by biosynthesis. Biosynthesis is carried out by introducing an enzyme gene involved in the curcumin synthesis pathway into Escherichia coli, and culturing it in a medium containing a precursor substance that is the material for the derivative, thereby synthesizing the curcumin. In this way, derivatives with different functional groups can be easily obtained. Also, specific carbons are replaced with stable isotopes.

[0035] An overview of the biosynthesis is shown in Figure 1. A plasmid carrying the genes for the enzymes that synthesize curcumin (4CL, DCS, CURS1) is introduced into E. coli. The introduced E. coli is designated "mut-ecoil." This E. coli is cultured in a medium containing two compounds that serve as precursors of curcumin (referred to as precursor P1 and precursor P2, respectively). These two precursors are phenylpropionic acid to which functional groups have been bound, and in Figure 1 they are designated Rp1 and Rp2. There are no particular restrictions on these functional groups.

[0036] Mutant E. coli synthesizes curcumin analogues from these precursors without any discrimination between the precursors, resulting in three types of analogues: precursor P1 used at both the left and right sites (homo-P1), precursors P1 and P2 used at both the left and right sites (hetero-P1_P2), and precursor P2 used at both the left and right sites (homo-P2).

[0037] For example, if precursor P1 and precursor P2 are both hydroxymethoxyphenylpropionic acid of formula (100), the three synthesized species will all be curcumin.

[0038] [ka]

[0039] The curcumin derivative thus obtained undergoes keto-enol tautomerization, as shown in formula (101).

[0040] [ka]

[0041] Therefore, the oxygen atoms at the 2- and 2'-positions are bonded together with difluoroboron. This is called "BF2 conversion." As a result, BF2-converted curcumin is produced, as shown in formula (102).

[0042] [ka]

[0043] The tautomerization of BF2-modified curcumin shown in formula (102) disappears, and the BF2-modified curcumin, which exists in a stable structure, has the property of emitting fluorescence. By changing the functional groups bonded to the benzene rings at the left and right sites, the fluorescence emission in the infrared band can be increased to an intensity sufficient for observation.

[0044] Furthermore, by adjusting the functional groups bound to the benzene rings at the left and right sites, it is possible to impart specific binding strength to amyloid fibrils.

[0045] In addition, the medium used for culturing 13 By incorporating C glucose, the carbon at position 1 (see formula 100) can also be modified with a stable isotope. 13 With C, it is possible to image with MRI, and detailed images of amyloid fibrils in the brain are possible. In addition, since it is converted to BF2, it has F in the skeleton. Therefore, nuclear magnetic resonance imaging using F is also possible.

[0046] As described above, the amyloid fiber detection probe according to the present invention is made of a curcumin derivative and has the ability to emit fluorescence in the infrared region, and therefore can be observed even when present several centimeters beneath the skin using an infrared camera or the like.

[0047] In addition, the amyloid fiber detection probe according to the present invention contains boron in the skeleton due to the conversion to BF2. Boron clusters are used in neutron capture therapy, but how to deliver the boron clusters to the target is an issue. However, the amyloid fiber detection probe according to the present invention not only binds to amyloid fibers but also has boron in the skeleton. Therefore, the position of amyloid fibers can be identified by fluorescence emission in the infrared range and can be simultaneously targeted for neutron irradiation, and can be used as a composition for neutron capture therapy. EXAMPLES

[0048] Curcumin analogs were produced and purified as follows: Three enzyme genes for the curcumin synthesis pathway, 4CL, DCS, and CURS1, were introduced into Escherichia coli BL21(DE3) via plasmid.

[0049] After overnight shaking culture at 37°C in TB medium, the culture temperature was lowered to 27°C, isopropyl-β-thiogalactopyranoside (IPTG, final concentration 1 mM) was added, and further overnight shaking culture was continued. A precursor dissolved in DMSO to a concentration of 10 mg / mL was added in an amount of 1 / 1000 of the medium, and further cultured for 24 hours. The cells were collected by centrifugation, dissolved in PBS(-), and stored at -30°C. The culture supernatant was stored at 4°C.

[0050] Lipid-soluble metabolites were extracted from the fungal cells using the Bligh & Dyer method, then spray-dried. The metabolites were dissolved in methanol, and the presence of curcumin analogues was confirmed by TLC. They were then purified using a silica column (10 mL). 1 mL of the eluted fraction was collected and promptly dried. After suspending in methanol, fractions containing curcumin analogues were identified by TLC and collected. At this point, the absorption and fluorescence spectra were measured.

[0051] Lipid-soluble substances in the culture supernatant were extracted by solid-phase extraction using a C18 sep-pak column, spray-dried, and suspended in methanol, and then purified using a silica column in the same manner as the curcumin analogues derived from the fungus body.

[0052] The precursors used are shown in Figure 2. Eight precursors were used: precursor-8, precursor-13, precursor-14, precursor-15, precursor-18, precursor-22, precursor ferulate, and precursor coumalate. The precursor ferulate and precursor coumalate are hydroxymethoxyphenylpropionic acid and methoxyphenylpropionic acid, respectively. These were used to produce curcumin analogs. Table 1 shows the precursors used (referred to as the first and second precursors, respectively) and the sample names and sample numbers of the curcumin analogs.

[0053] [Table 1]

[0054] Curu8 and curu9 are the same substance but produced on different days. Curu14 and curu15 were obtained from the inside (ppt) and outside (supernatant) of E. coli, respectively, and were the same substance.

[0055] <BF2 modification of curcumin analogues> The curcumin analogs in Table 1 were transferred to glass vials, and after inserting a stir bar, the vials were completely dried and then sealed. A syringe filled with N2 was inserted into the vial, and the oxygen and water vapor in the vial were replaced with N2. 250 μL of dichloromethane (DCM), which had been dehydrated using a molecular sieve from the previous day, was injected into the vial while stirring with a stirrer to completely dissolve the curcumin analogs. 250 μL of boron trifluoride diethyl ether complex mixed with DCM in a 1:1 ratio was slowly added while stirring with a stirrer, and the mixture was left at room temperature for more than 2 hours.

[0056] After the reaction, the mixture was repeatedly dried and washed with diethyl ether to remove unreacted boron trifluoride diethyl ether complex. After complete drying, the mixture was suspended in methanol, filtered through a PFTE filter, and stored at 4°C. The absorption and fluorescence spectra were measured at this point. Table 2 shows the BF2-modified curcumin analogues. The structures of each compound are shown in Figures 3 to 5. The structures of Compounds 1 to 15 are represented by Formulas (1) to (15), respectively. Compound 1 is curcumin itself, and is the same as Formula (103).

[0057] [Table 2]

[0058] <Light Emitting Characteristics> The luminescence properties of the BF2-modified curcumin analogue change compared to before BF2 conversion. In particular, the luminescence in the infrared region becomes stronger. Figure 6 shows the luminescence properties of compound 1 (curcumin) and curu1 (curcumin itself before BF2 conversion). Figure 6(a) shows curu1, and Figure 6(b) shows compound 1.

[0059] In each graph, the horizontal axis is the excitation light wavelength (nm) and the vertical axis is the emission intensity (unitless). The wavelength of the fluorescence emitted for each excitation light wavelength is indicated by vertical numbers above the bar graph.

[0060] When excited at a wavelength of 635 nm, curu1 without BF2 hardly emitted any fluorescence, but the BF2-modified curcumin analog compound 1 emitted fluorescence in the infrared region at 700 nm. Similarly, the other compounds 2 to 15 emitted fluorescence in the infrared region.

[0061] <Binding to amyloid fibrils> The mechanism by which amyloid beta is produced is thought to be as follows: Amyloid beta is produced when it is cleaved from the amyloid precursor protein (APP) by a protease. When APP is cleaved by alpha-secretase, amyloid beta is not produced. On the other hand, when APP is cleaved by beta-secretase (→ on the left side of the figure), it is then cleaved by gamma-secretase, producing amyloid beta. A component of gamma-secretase is presenilin (PS2), which regulates gamma-secretase activity.

[0062] In this study, the researchers co-expressed the APP mutant found in familial Alzheimer's disease patients with the PS2 mutant in cells and confirmed the production of amyloid beta. They also confirmed that amyloid beta was not produced in the absence of APP expression.

[0063] An example is shown in Figure 7. Figure 7(a) shows the electrophoresis of extracts from cells in which APP mutants and PS2 mutants were co-expressed, and labeled with an anti-amyloid β antibody (labeled "anti-Aβ" in the figure). Amyloid β oligomers were confirmed at approximately 40 kDa.

[0064] Figure 7(b) shows the results of SDS-PAGE after contacting cell extract with compound 10 (hetero-13-14-BF2). The vertical axis indicates mass (kDa) and the horizontal axis indicates sample type. When compound 10 was contacted with 10 μL of APP / PS2 extract at concentrations of 0, 2, 4, 6, and 8 μM, concentration-dependent luminescence was observed at the same mass position as in electrophoresis. From the above, it was confirmed that compound 10 binds to amyloid β.

[0065] Figure 8 shows the results of similar experiments performed with other compounds. As a result of SDS-PAGE, it was confirmed that Compound 4, Compound 5, Compound 6, Compound 10, Compound 14, and Compound 15 (note that Compound 14 and Compound 15 are the same substance) have the ability to bind to amyloid β.

[0066] Figure 9 shows the results of Native-PAGE, which looked at the binding of each compound to α-synuclein amyloid fibrils, which are thought to be the cause of Parkinson's disease. It can be seen that Compounds 3, 4, 7, 8, and 9 (note that Compounds 8 and 9 are the same substance) bind to α-synuclein amyloid fibrils. [Industrial Applicability]

[0067] The amyloid fiber detection probe according to the present invention specifically binds to amyloid fibers and emits infrared light inside the body, which allows non-invasive observation from outside the body, and is therefore highly effective in detecting amyloid fibers. 13 It can be modified with C and F, and can be detected by nuclear magnetic resonance imaging, etc. Furthermore, since it has boron in its structure, it can be used as a composition for neutron capture therapy, and there is a possibility that amyloid fibrils can be destroyed by neutron beams.

Claims

1. Curcumin derivatives having structures represented by formulas (2) to (8) and formulas (10) to (14). 【Chemistry 101】 【Chemistry 102】 【Chemistry 103】 【Chemistry 104】 【Chemistry 105】 【Chemistry 106】 【Chemistry 107】 【Chemistry 108】 【Chemistry 109】 【Chemistry 110】 【Chemistry 111】 【Chemistry 112】

2. An amyloid fiber detection probe that binds to amyloid-β amyloid fibers, comprising at least one curcumin derivative represented by formula (4), formula (5), formula (6), formula (10), or formula (14). 【Chemistry 114】 【Chemistry 115】 【Chemistry 116】 【Chemistry 117】 【Chemistry 118】

3. The amyloid fibril detection probe according to claim 1 , wherein at least one carbon in the amyloid fibril detection probe is isotopically modified.

4. An amyloid fibril detection probe that binds to α-synuclein amyloid fibrils, comprising at least one curcumin derivative represented by formula (3), formula (4), formula (7), or formula (8). 【Chemistry 119】 【Chemistry 120】 【Chemistry 121】 【Chemistry 122】

5. The amyloid fibril detection probe according to claim 3, wherein at least one carbon in the amyloid fibril detection probe is isotopically modified.

6. A composition for neutron radiation therapy, comprising the amyloid fiber detection probe according to any one of claims 1 to 4.

7. A composition for neutron radiation therapy, comprising a compound that selectively binds to amyloid fibrils and has boron in its structure.

Citation Information

Patent Citations

  • Curcumin derivative, its manufacturing method, and photoacoustic imaging agent containing the same for detecting beta-amyloid plaques

    JP2019536743A

  • Compound for boron neutron capture therapy for amyloid β diseases

    JP2020066619A

  • Curcumin-boron complex and pharmaceutical containing same

    WO2017164172A1

  • Benzothiazole derivative compounds, compositions and uses

    JP2006522104A

  • Novel methods for screening amyloidosis-treating agents and pharmaceutical compositions for amyloidosis

    JP2020188700A